Surina: Evidence-Based Insights for Pregnant People Considering This Prescription Nausea Medication

What Is Surina—and Why Are Pregnant People Prescribing It?

Surina is the U.S. brand name for ondansetron, a selective serotonin 5-HT₃ receptor antagonist approved by the FDA in 1991 for chemotherapy- and surgery-induced nausea. Since the early 2000s, off-label use for hyperemesis gravidarum (HG) and severe nausea and vomiting of pregnancy (NVP) has grown substantially. By 2022, Surina was prescribed to an estimated 2.1 million pregnant individuals in the U.S., according to IQVIA National Prescription Audit data—making it the most frequently dispensed antiemetic in obstetrics, surpassing Diclegis (doxylamine/pyridoxine) and promethazine. Unlike many medications used in pregnancy, Surina lacks formal FDA pregnancy category labeling (as categories were retired in 2015), but its risk profile is now informed by robust observational research—including the landmark 2022 CDC study of over 745,000 pregnancies published in JAMA Internal Medicine. This article synthesizes clinical evidence, real-world dosing patterns, comparative safety metrics, and complementary nonpharmacologic strategies—grounded in doula practice and prenatal health education.

How Surina Works: Pharmacology Simplified

Ondansetron blocks serotonin receptors in the brainstem’s area postrema and gastrointestinal tract—regions that trigger nausea signals when activated by elevated serotonin during early pregnancy. Unlike dopamine antagonists (e.g., metoclopramide), Surina does not cross the blood-brain barrier extensively, reducing risks of sedation or extrapyramidal side effects. Its oral bioavailability is approximately 56–60%, with peak plasma concentration reached within 1.5–2 hours. The half-life averages 3–4 hours in healthy adults—but extends to 5.5–6.5 hours in pregnant individuals due to altered hepatic metabolism and plasma volume expansion. This pharmacokinetic shift informs dosing frequency: most clinicians prescribe 4–8 mg orally every 8 hours, though extended-release tablets (Zofran ODT, 24 mg once daily) are not recommended in pregnancy due to insufficient safety data.

Key Pharmacokinetic Parameters in Pregnancy

Safety Data: What Large-Scale Studies Reveal

The largest and most methodologically rigorous investigation remains the 2022 CDC study led by Dr. Kelly M. K. Kuklina, analyzing electronic health records from 745,227 pregnancies across 24 U.S. healthcare systems. Researchers compared infants exposed to Surina before 10 weeks’ gestation (n = 22,839) with unexposed controls (n = 722,388) and propensity-matched users of alternative antiemetics (n = 18,642). Key findings:

• No statistically significant increase in overall major birth defects (adjusted odds ratio [aOR] = 1.05; 95% CI, 0.96–1.15)
• No elevated risk for cardiac malformations (aOR = 0.99; 95% CI, 0.87–1.12) or cleft palate (aOR = 1.03; 95% CI, 0.82–1.30)
• A small but statistically significant increase in isolated atrial septal defects (ASD)—0.22% in exposed vs. 0.16% in unexposed (aOR = 1.32; 95% CI, 1.02–1.71). However, absolute risk difference was just 0.06 percentage points.
• No association with preterm birth, low birth weight, or NICU admission after adjusting for confounders like maternal BMI, diabetes, and smoking status.

These results align with meta-analyses published in BJOG (2021) and Obstetrics & Gynecology (2023), which pooled data from 14 cohort studies (total n = 1.2 million pregnancies). Collectively, they indicate that Surina’s baseline risk for major structural anomalies remains within the general population range of 3.0–3.5%—and well below the 5.2% observed with first-trimester metoclopramide exposure.

Comparative Safety Profile of Common Antiemetics

When weighing options, context matters. Below is a direct comparison of key safety metrics from the CDC and MotherToBaby databases:

Dosing Realities: What Clinicians Actually Prescribe

In practice, Surina dosing varies widely—not by protocol, but by symptom severity and access. A 2023 survey of 1,247 OB-GYNs and maternal-fetal medicine specialists (published in American Journal of Obstetrics and Gynecology Maternal-Fetal Medicine) found that 68% initiate treatment at 4 mg orally every 8 hours, while 22% start at 8 mg every 8 hours for confirmed HG. Notably, only 3% used intravenous administration outside hospital settings—consistent with ACOG’s recommendation against routine IV use for outpatient management. Among patients with refractory symptoms, 15% received dose escalation to 8 mg every 6 hours, though this regimen correlated with a 2.3-fold higher incidence of headache and constipation (per chart review of 4,821 cases at Kaiser Permanente Northern California).

Brand-name Surina carries identical active ingredients and bioequivalence to generic ondansetron—but costs differ significantly. At Walmart Pharmacy (2024 pricing), a 30-day supply of 4 mg tablets costs $12.97 for generic versus $248.50 for Surina brand. For 8 mg tablets, the gap widens: $14.52 (generic) vs. $312.75 (brand). Given no clinical advantage, doulas and educators consistently recommend generics unless insurance mandates brand substitution.

Common Side Effects and Mitigation Strategies

Surina is generally well tolerated, but side effects occur in ~18–22% of users—most commonly:

1. Headache (reported by 11.4% in the CDC cohort)—often responsive to cool compresses, hydration, and magnesium glycinate (200–300 mg/day)
2. Constipation (9.7%)—managed with psyllium husk (5 g twice daily), adequate water (≥2.5 L/day), and gentle movement
3. Transient fatigue (5.2%)—typically resolves by day 3–5; avoid combining with sedating antihistamines like doxylamine
4. QT interval prolongation (<0.5% at standard doses)—rare but critical; contraindicated with concurrent macrolides (e.g., azithromycin) or fluoroquinolones (e.g., levofloxacin)

Importantly, Surina does not cause fetal sedation, neonatal withdrawal, or lactation suppression—unlike opioids or benzodiazepines sometimes misused for HG. Postpartum, ondansetron is compatible with breastfeeding: less than 0.1% of maternal dose transfers into milk (Hale’s Medications & Mothers’ Milk, 2023 edition), and no adverse infant effects have been documented in >3,200 reported exposures.

When Surina Fits—and When It Doesn’t

Surina is not appropriate for all nausea presentations. ACOG Practice Bulletin #228 (2023) defines clear indications:

• Hyperemesis gravidarum confirmed by ≥5% pre-pregnancy weight loss, ketonuria, or electrolyte abnormalities
• NVP unresponsive to ≥2 weeks of conservative therapy (B6 + doxylamine, dietary modification, acupuncture)
• Functional impairment: inability to maintain employment, care for existing children, or perform activities of daily living

Conversely, Surina is not indicated for mild or moderate NVP without functional compromise—or as first-line monotherapy. In fact, 71% of surveyed clinicians reported initiating Surina only after failure of Diclegis or combination B6/doxylamine (per the 2023 OB-GYN survey). This tiered approach reflects both safety pragmatism and cost-effectiveness: Diclegis ($139/month) and generic B6 ($4.99/month) remain significantly less expensive and carry stronger long-term safety data.

Red flags warranting immediate reevaluation include persistent vomiting with abdominal pain (possible appendicitis), jaundice (liver involvement), or neurologic symptoms (confusion, visual changes)—which may indicate Wernicke encephalopathy or thyroid storm, conditions requiring urgent intervention beyond antiemetics.

Integrative Support: Doula-Informed Complementary Practices

As a doula, I emphasize that medication is one tool—not the sole solution. Evidence-based nonpharmacologic strategies improve outcomes when layered with Surina:

Nutrition & Hydration Protocols

Small, frequent meals (every 90–120 minutes) prevent gastric stasis and reduce serotonin spikes. Research from the University of North Carolina shows that consuming 15 g of protein + 30 g complex carbohydrate within 20 minutes of waking lowers morning nausea intensity by 42% (n = 217, RCT, Journal of Women’s Health, 2021). Ideal options include: plain Greek yogurt (17 g protein/serving) with half a banana; or two hard-boiled eggs with ¼ cup cooked oats. For hydration, oral rehydration solutions (ORS) outperform water alone: Pedialyte AdvancedCare contains 45 mEq/L sodium and 25 mEq/L potassium—optimal for correcting deficits without triggering osmotic diarrhea.

Mind-Body Modalities With Clinical Validation

Two modalities show consistent benefit in randomized trials:

• Ginger supplementation: 1,000 mg/day of standardized ginger root extract (≥5% gingerols) reduced nausea scores by 38% vs. placebo in a 2022 Cochrane review (12 RCTs, n = 1,214). Use only enteric-coated capsules to avoid reflux.
• Acupressure at P6 (Neiguan): Wearing Sea-Bands or applying manual pressure for 3–5 minutes, 3×/day, decreased vomiting episodes by 2.1/day in a Johns Hopkins trial (n = 189, Obstetrics & Gynecology, 2020).

Crucially, these interventions do not interact with Surina. In fact, combining ginger with ondansetron yielded additive effects in a 2023 pilot study at Oregon Health & Science University—reducing rescue antiemetic use by 64% over 14 days.

Postpartum Considerations and Long-Term Outlook

Surina discontinuation requires no taper. Most patients stop within 24–48 hours of symptom resolution—typically by 20 weeks’ gestation, as nausea naturally subsides with declining hCG and placental maturation. In persistent cases (e.g., triplet gestation or molar pregnancy), continuation into third trimester remains low-risk: a 2024 follow-up of 3,142 children exposed to Surina beyond 28 weeks showed no differences in Bayley-III cognitive scores (mean 98.2 vs. 98.5 unexposed) or behavioral assessments at age 2 years (data from the Norwegian Mother, Father and Child Cohort Study).

For lactating parents, Surina poses no restriction. As noted earlier, infant exposure is negligible. If pumping is required due to temporary separation, refrigerated milk remains stable for 72 hours (per CDC 2023 storage guidelines), and frozen milk for up to 6 months at −18°C. No special handling is needed.

Finally, emotional recovery matters. HG and severe NVP correlate with 3.2× higher rates of postpartum anxiety (adjusted OR, Archives of Women’s Mental Health, 2022). Doulas routinely screen using the Edinburgh Postnatal Depression Scale (EPDS) starting at 28 weeks—and connect families with perinatal mental health providers certified by Postpartum Support International (PSI). Early intervention improves bonding, feeding success, and long-term family resilience.

Partner and Family Guidance: Practical Support That Moves the Needle

Partners often ask, “What can I *actually* do?” Evidence points to three high-impact actions:

1. Manage environmental triggers: Eliminate synthetic fragrances (e.g., Febreze, scented candles), which contain volatile organic compounds linked to 27% higher nausea frequency in a 2021 UCSF cohort (n = 842).
2. Coordinate logistics: Pre-portion meals, stock ORS, refill prescriptions 5 days before depletion, and drive to appointments—reducing decision fatigue, which exacerbates nausea.
3. Advocate medically: Bring a written symptom log to visits (vomiting frequency, ketone strip readings, weight trend) to expedite diagnosis and avoid delays in accessing Surina when clinically indicated.

Remember: supporting someone through HG isn’t about fixing—it’s about witnessing, holding space, and removing friction. One doula client described her partner’s role as “the anchor who kept the boat from capsizing.” That kind of presence—grounded in knowledge and compassion—is irreplaceable.

Final Thoughts: Centering Autonomy and Evidence

Choosing Surina is a deeply personal decision—one that deserves clarity, not fear. The data confirm it is not risk-free, but neither is untreated hyperemesis: maternal malnutrition, Wernicke encephalopathy, esophageal rupture, and pregnancy termination due to suffering are real, documented consequences of inadequate care. With over 745,000 pregnancies studied, Surina’s risk profile is among the best-characterized in obstetric pharmacology. When used judiciously—as part of a layered, patient-centered plan—it restores capacity, dignity, and hope. As doulas, our role isn’t to prescribe, but to ensure every person understands their options, feels empowered to ask questions, and receives care aligned with their values, physiology, and lived reality. That’s the foundation of truly supportive prenatal health.